Jorge A. Garcia, MD, discusses the safety of Lu 177 vipivotide tetraxetan earlier in the treatment course for PSMA–positive mCRPC.
Jorge A. Garcia, MD
Advertisement
Jorge A. Garcia, MD is the current director of the GU Medical Oncology clinical and research programs at University Hospitals Seidman Cancer Center.
Articles by Jorge A. Garcia, MD
Jorge A. Garcia, MD, discusses the clinical impact of the FDA’s expanded approval of lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mCRPC.
Jorge A. Garcia, MD, Department of Hematology and Oncology, discusses the results of the phase III METEOR trial, which compared the efficacy of cabozantinib (Cabometyx) versus everolimus (Afinitor) in patients with advanced renal cell carcinoma.
Jorge A. Garcia, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses some of the challenges with immunotherapy in prostate cancer.
Advertisement
Latest Updated Articles
Dr. Jorge Garcia on METEOR Trial for RCCPublished: July 7th 2016 | Updated:
Dr. Garcia on Challenges With Immunotherapy in Prostate CancerPublished: April 1st 2015 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
Nuvisertib Yields Strong Safety, Promising Efficacy in R/R Myelofibrosis
5